Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men.
about
In vitro and in vivo activities of the hydroxynaphthoquinone 566C80 against the cyst form of Toxoplasma gondiiAtovaquone nanosuspensions show excellent therapeutic effect in a new murine model of reactivated toxoplasmosisRifabutin is active in murine models of toxoplasmosisLC-APCI mass spectrometric method development and validation for the determination of atovaquone in human plasma.Antiparasitic agent atovaquoneAntimalarial pharmacology and therapeutics of atovaquoneOpportunistic infections in HIV-infected patients.Pharmacokinetics and bioavailability of fluconazole in patients with AIDS.Drug-resistant malaria: molecular mechanisms and implications for public health.Malaria prophylaxis in patients with renal impairment: a review.Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients.In vitro and in vivo activities of the hydroxynaphthoquinone atovaquone alone or combined with pyrimethamine, sulfadiazine, clarithromycin, or minocycline against Toxoplasma gondii.Atovaquone: a review.A validated method for development of atovaquone as API and tablet dosage forms by UV spectroscopy.Examination of some factors responsible for a food-induced increase in absorption of atovaquone.Population pharmacokinetics of atovaquone in patients with acute malaria caused by Plasmodium falciparum.Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study.Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement.
P2860
Q28320236-27E062D1-7210-4D88-A992-465714383297Q28365205-26760AD8-C2E0-43D2-8E96-7AA07325BDB7Q28378281-576B2EFD-AFE8-40C7-B3DB-BE457E9FDE5EQ33497387-2B5901D3-76CA-4280-BA5B-71DD4A180462Q34107885-F14CAFB6-E045-4D18-A708-EB286EA413CCQ35131253-F620F2AC-7DDA-4F09-871C-68A50A4258E7Q35893214-6F876E35-8146-4672-A8F7-223E9BB4B98FQ35897483-EF8DF105-BACB-42A4-A97E-2BDCAE6E1DC3Q37870388-955856EC-F63E-490A-A7FB-BCC1693A1E7DQ38078263-E7D752B2-4857-428E-A8CE-9AB1234A4B5EQ39781539-F28AD9C7-0A6C-4AF2-ABAE-EA37F9CB8FB4Q39882492-B72973B2-AB77-457D-8FA2-C3C758517434Q40709114-78204BBD-8BBC-4DA4-B984-0062D0329FCEQ40829190-82F50B09-B1C6-4585-B3A8-DBD018615A9FQ41907361-21C863E2-F485-495F-9F0D-5C35B55A5AA4Q48036778-7E1425CD-2CA1-4624-AF55-D0AEFC1D99FEQ51559180-97AA4327-7521-4AAE-885C-C0DFFA968CCCQ51567230-DC34DBCD-88CB-4F2E-B082-4A0F66DF0D20
P2860
Safety and pharmacokinetics of 566C80, a hydroxynaphthoquinone with anti-Pneumocystis carinii activity: a phase I study in human immunodeficiency virus (HIV)-infected men.
description
1991 nî lūn-bûn
@nan
1991年の論文
@ja
1991年学术文章
@wuu
1991年学术文章
@zh
1991年学术文章
@zh-cn
1991年学术文章
@zh-hans
1991年学术文章
@zh-my
1991年学术文章
@zh-sg
1991年學術文章
@yue
1991年學術文章
@zh-hant
name
Safety and pharmacokinetics of ...... ency virus (HIV)-infected men.
@en
Safety and pharmacokinetics of ...... ency virus (HIV)-infected men.
@nl
type
label
Safety and pharmacokinetics of ...... ency virus (HIV)-infected men.
@en
Safety and pharmacokinetics of ...... ency virus (HIV)-infected men.
@nl
prefLabel
Safety and pharmacokinetics of ...... ency virus (HIV)-infected men.
@en
Safety and pharmacokinetics of ...... ency virus (HIV)-infected men.
@nl
P2093
P356
P1476
Safety and pharmacokinetics of ...... ency virus (HIV)-infected men.
@en
P2093
Hetherington SV
Lancaster DJ
Rosenbaum D
P304
P356
10.1093/INFDIS/163.4.843
P407
P577
1991-04-01T00:00:00Z